Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508270 | 0.97 | BACE1 (0.53) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3507613 | 0.93 | BACE1 (0.57) | BACE1BACE2CTSDAPP | |
| SCHEMBL3510037 | 0.93 | BACE1 (0.61) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3511775 | 0.92 | BACE1 (0.62) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3511388 | 0.92 | BACE1 (0.62) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3507271 | 0.90 | BACE1 (0.56) | BACE1BACE2CTSDAPP | |
| SCHEMBL3508169 | 0.90 | BACE2 (0.58) | BACE1BACE2CYP3A4CTSD | |
| SCHEMBL3510786 | 0.90 | BACE1 (0.58) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3507963 | 0.90 | BACE1 (0.58) | BACE1BACE2CYP3A4CTSDAPP | |
| SCHEMBL3512909 | 0.89 | BACE1 (0.54) | BACE1BACE2CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP3A4 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.